Search Results

RegeneRx Biopharmaceuticals, Inc. announced that, pursuant to the company’s consent solicitation dated July 11, 2023, holders of 48.5% of the Company’s outstanding stock have voted to date, with 94% voting in favor of the proposed reverse stock split.

RegeneRx Biopharmaceuticals, Inc. announced that it has today effected a 1-for-100 reverse split in the outstanding shares of Common Stock of the Company and has filed the requisite Form 15 to suspend and terminate the Company’s continued obligations to file reports with the SEC pursuant to Sections 13(d) and 15(d) of the Securities Exchange Act of 1934, as amended.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.

RegeneRx Biopharmaceuticals, Inc. announced that, pursuant to the company’s consent solicitation dated July 11, 2023, it has received consents as of August 3, 2023 from the holders of 51.07% of the Company’s Common Stock in favor of the proposed reverse stock split, which is a prerequisite to allowing the Company to suspend its public reporting obligations under the Securities Exchange Act of 1934 and become a non-reporting, privately held company.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.

RegeneRx Biopharmaceuticals, Inc. has issued a Letter to Stockholders updating development of product candidates.

RegeneRx Biopharmaceuticals, Inc. today announced that GtreeBNT, the licensee for several RegeneRx products, is being acquired by HLB Group, a Korean company

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), today announced that it has entered into a definitive agreement with certain institutional and accredited investors, including certain directors and officers of the Company, in connection with a private placement of up to $2,000,000 of shares of its common stock and warrants at a purchase price of $0.20 per share and accompanying warrants